Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT), a two-arm, randomized, observer-blind, controlled phase IIb national multicentre clinical trial: study protocol

Authors: Driedger, Jan H.¹ (AUTHOR), Schröter, Julian¹ (AUTHOR), Hertzberg, Christoph (AUTHOR), Weschke, Bernhard (AUTHOR), Kaindl, Angela M. (AUTHOR), Lücke, Thomas (AUTHOR), Thiels, Charlotte (AUTHOR), Klotz, Kerstin Alexandra (AUTHOR), Fazeli, Walid (AUTHOR), Rostásy, Kevin (AUTHOR), Wiethoff-Ubrig, Lucia (AUTHOR), Kaiser, Olaf (AUTHOR), Trollmann, Regina (AUTHOR), Mammadova, Dilbar (AUTHOR), Schubert-Bast, Susanne (AUTHOR), Bach, Alexia (AUTHOR), Eckenweiler, Matthias (AUTHOR), Schönberger, Jan (AUTHOR), Martakis, Kyriakos (AUTHOR), Hahn, Andreas (AUTHOR)

Source: Orphanet Journal of Rare Diseases. 1/6/2025, Vol. 20, p1-10. 10p.

Subject Terms: *TUBEROUS sclerosis, *MTOR inhibitors, *BODY surface area, *CLINICAL trials, *INFANTILE spasms, *TODDLERS development

Chylothorax as Part of Lymphatic Cystic Malformations Developing in Adulthood.

Alternate Title: Yetişkinlikte Ortaya Çıkan Lenfatik Kistik Malformasyonların Bir Parçası Olarak Şilotoraks.

Authors: Andaloussi, Meryem Karhate¹ mariam.karhateandaloussi@usmba.ac.ma, Senhaji, Lamiyae¹, Amara, Bouchra¹, Serraj, Mounia¹

Source: Respiratory Case Reports. 2025, Vol. 14 Issue 1, p1-6. 6p.

Subject Terms: *LYMPHATIC abnormalities, *MTOR inhibitors, *MUCOUS membranes, *CHYLOTHORAX, *GENETIC mutation

Targeting mTOR Kinase with Natural Compounds: Potent ATP-Competitive Inhibition Through Enhanced Binding Mechanisms.

Authors: Marafie, Sulaiman K.¹ (AUTHOR) sulaiman.marafie@dasmaninstitute.org, Alshawaf, Eman¹ (AUTHOR) eman.alshawaf@dasmaninstitute.org, Al-Mulla, Fahd² (AUTHOR) fahd.almulla@dasmaninstitute.org, Abubaker, Jehad¹ (AUTHOR) jehad.abubakr@dasmaninstitute.org, Mohammad, Anwar¹ (AUTHOR) jehad.abubakr@dasmaninstitute.org

Source: Pharmaceuticals (14248247). Dec2024, Vol. 17 Issue 12, p1677. 17p.

Subject Terms: *MTOR inhibitors, *CHINESE medicine, *CATALYTIC domains, *DYNAMIC stability, *CELL physiology

The mTOR pathway controls phosphorylation of BRAF at T401.

Authors: Christen, Daniel^1,2,3 (AUTHOR), Lauinger, Manuel^1,2 (AUTHOR), Brunner, Melanie⁴ (AUTHOR), Dengjel, Jörn⁴ (AUTHOR), Brummer, Tilman^1,3,5,6 (AUTHOR) tilman.brummer@mol-med.uni-freiburg.de

Source: Cell Communication & Signaling. 9/2/2024, Vol. 22 Issue 1, p1-13. 13p.

Subject Terms: *HUMAN origins, *MTOR inhibitors, *GROWTH factors, *BRAF genes, *SUBSTRATES (Materials science)

mTOR and SGLT-2 Inhibitors: Their Synergistic Effect on Age-Related Processes.

Authors: Troise, Dario^1,2 (AUTHOR) dario.troise@unifg.it, Mercuri, Silvia¹ (AUTHOR), Infante, Barbara¹ (AUTHOR), Losappio, Vincenzo¹ (AUTHOR), Cirolla, Luciana¹ (AUTHOR), Netti, Giuseppe Stefano³ (AUTHOR), Ranieri, Elena³ (AUTHOR), Stallone, Giovanni¹ (AUTHOR)

Source: International Journal of Molecular Sciences. Aug2024, Vol. 25 Issue 16, p8676. 23p.

Subject Terms: *MTOR inhibitors, *CELL growth, *DRUG development, *MEDICAL care costs, *AGING

A comparative analysis of clinical outcomes between conversion to mTOR inhibitor and calcineurin inhibitor reduction in managing BK viremia among kidney transplant patients.

Authors: Cho, Ara¹ (AUTHOR), Park, Sunghae² (AUTHOR), Han, Ahram¹ (AUTHOR), Ha, Jongwon¹ (AUTHOR), Park, Jae Berm² (AUTHOR), Lee, Kyo Won² (AUTHOR), Min, Sangil¹ (AUTHOR) surgeonmsi@gmail.com

Source: Scientific Reports. 6/4/2024, Vol. 14 Issue 1, p1-10. 10p.

Subject Terms: *KIDNEY transplantation, *MTOR inhibitors, *CALCINEURIN, *TREATMENT effectiveness, *TACROLIMUS, *RAPAMYCIN, *VIREMIA

mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process.

Authors: Marafie, Sulaiman K.¹ (AUTHOR) sulaiman.marafie@dasmaninstitute.org, Al-Mulla, Fahd² (AUTHOR) fahd.almulla@dasmaninstitute.org, Abubaker, Jehad¹ (AUTHOR) sulaiman.marafie@dasmaninstitute.org

Source: International Journal of Molecular Sciences. Jun2024, Vol. 25 Issue 11, p6141. 17p.

Subject Terms: *METABOLIC disorders, *MTOR inhibitors, *AGING, *CELL physiology, *PROTEIN synthesis

Inhibition of PIKfyve Leads to Lysosomal Disorders via Dysregulation of mTOR Signaling.

Authors: Xia, Jianhong¹ (AUTHOR) jhxia2006@163.com, Wang, Haiyun^1,2 (AUTHOR) sunny.haiyun@gmail.com, Zhong, Zhihang^3,4 (AUTHOR) zhongzhihanggood@163.com, Jiang, Jun^3,4 (AUTHOR) jiangjun@scau.edu.cn

Source: Cells (2073-4409). Jun2024, Vol. 13 Issue 11, p953. 18p.

Subject Terms: *LYSOSOMAL storage diseases, *MTOR inhibitors, *CELL culture, *BRACHYDANIO, *HOMEOSTASIS

Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.

Authors: Johnson, Jan¹ (AUTHOR), Somerfield, Wendy² (AUTHOR), Johnson, Simon R.^1,2,3 (AUTHOR) simon.johnson@nottingham.ac.uk

Source: Orphanet Journal of Rare Diseases. 3/26/2024, Vol. 19 Issue 1, p1-8. 8p.

Subject Terms: *TUBEROUS sclerosis, *MTOR inhibitors, *LUNG transplantation, *TREATMENT delay (Medicine)

Geographic Terms: UNITED Kingdom

A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors.

Authors: Sonis, Stephen T.^1,2,3 (AUTHOR) ssonis@biomodels.com, Villa, Alessandro^4,5 (AUTHOR)

Source: Cancers. Jan2024, Vol. 16 Issue 1, p68. 11p.

Subject Terms: *CANKER sores, *MTOR inhibitors, *ORAL diseases, *HYPOTHESIS, *ORAL mucosa

mTORC1 inhibition may improve T lymphocytes affected by aging.

Authors: Asghari, F.¹, Karimi, M. H.^2,3, Pourfathollah, A. A.¹ pourfa@modares.ac.ir

Source: Immunopharmacology & Immunotoxicology. Dec2023, Vol. 45 Issue 6, p719-729. 11p.

Subject Terms: *T cells, *MTOR inhibitors, *OXIDATIVE stress, *GENE expression, *CELL proliferation, *CD28 antigen, *IMMUNOSENESCENCE

Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors.

Authors: Wang, Jiani¹ (AUTHOR), Gui, Lin¹ (AUTHOR), Mu, Yuxin¹ (AUTHOR), Wang, Jiayu¹ (AUTHOR), Chi, Yihebali¹ (AUTHOR), Liu, Zhenteng² (AUTHOR), Li, Qing¹ (AUTHOR) cheryliqing@126.com, Xu, Binghe^1,3 (AUTHOR) xubinghebm@163.com

Source: BMC Cancer. 12/6/2023, Vol. 23 Issue 1, p1-12. 12p.

Subject Terms: *MTOR inhibitors, *ORAL drug administration, *ALANINE aminotransferase, *CHINESE people, *ASPARTATE aminotransferase, *RAPAMYCIN

mTOR Inhibitor Rapalink-1 Prevents Ethanol-Induced Senescence in Endothelial Cells.

Authors: Zhou, Huakang¹ (AUTHOR) sajjad.muhammad@med.uni-duesseldorf.de, Li, Xuanchen¹ (AUTHOR), Rana, Majeed² (AUTHOR), Cornelius, Jan Frederick¹ (AUTHOR), Khan, Dilaware¹ (AUTHOR) dilaware.khan@med.uni-duesseldorf.de, Muhammad, Sajjad^1,3,4 (AUTHOR)

Source: Cells (2073-4409). Nov2023, Vol. 12 Issue 22, p2609. 13p.

Subject Terms: *ENDOTHELIAL cells, *MTOR inhibitors, *GENE expression, *MTOR protein, *CARDIOVASCULAR diseases risk factors, *DNA damage

PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities.

Authors: Wiese, Wojciech¹ (AUTHOR) wojciech.wiese@stud.umed.lodz.pl, Barczuk, Julia¹ (AUTHOR) julia.barczuk@stud.umed.lodz.pl, Racinska, Olga¹ (AUTHOR) olga.racinska@stud.umed.lodz.pl, Siwecka, Natalia¹ (AUTHOR) natalia.siwecka@stud.umed.lodz.pl, Rozpedek-Kaminska, Wioletta¹ (AUTHOR) wioletta.rozpedek@umed.lodz.pl, Slupianek, Artur² (AUTHOR) aslupian@temple.edu, Sierpinski, Radoslaw³ (AUTHOR) r.sierpinski@uksw.edu.pl, Majsterek, Ireneusz¹ (AUTHOR) ireneusz.majsterek@umed.lodz.pl

Source: Cancers. Nov2023, Vol. 15 Issue 21, p5297. 18p.

Subject Terms: *PHOSPHOTRANSFERASES, *MTOR inhibitors, *LEUKEMIA, *CELLULAR signal transduction, *CELL cycle, *HEMATOLOGIC malignancies, *CELL proliferation

PIK3CA-related overgrowth spectrum (PROS) presenting as isolated macrodactyly.

Authors: Krishnamurthy, Kritika¹ (AUTHOR) kritikakrishnamurthy@yahoo.com, Edema, Ukuemi¹ (AUTHOR), Ustun, Berrin^1,2 (AUTHOR), Villanueva-Siles, Esperanza^1,3 (AUTHOR), Koehler, Steven M^3,4 (AUTHOR), Naeem, Rizwan^1,3 (AUTHOR), Wang, Yanhua^1,3 (AUTHOR), Goldstein, Doctor Y^1,3 (AUTHOR)

Source: Journal of Surgical Case Reports. Oct2023, Vol. 2023 Issue 10, p1-4. 4p.

Subject Terms: *MTOR inhibitors, *DISEASE progression, *SYMPTOMS, *LIPOMATOSIS, *CONGENITAL disorders

Inhibition of mTOR differently modulates planar and subepithelial fibrogenesis in human conjunctival fibroblasts.

Authors: Watanabe, Megumi¹ (AUTHOR) watanabe@sapmed.ac.jp, Tsugeno, Yuri¹ (AUTHOR), Sato, Tatsuya^2,3 (AUTHOR), Higashide, Megumi¹ (AUTHOR), Umetsu, Araya¹ (AUTHOR), Furuhashi, Masato² (AUTHOR), Ohguro, Hiroshi¹ (AUTHOR) ooguro@sapmed.ac.jp

Source: Graefe's Archive of Clinical & Experimental Ophthalmology. Jan2025, Vol. 263 Issue 1, p33-46. 14p.

Subject Terms: *MTOR inhibitors, *GENE expression, *CELL proliferation, *FIBROBLASTS, *PROTEIN expression

Downregulation of semaphorin 4A in keratinocytes reflects the features of non-lesional psoriasis.

Authors: Miki Kume¹, Hanako Koguchi-Yoshioka^1,2, Shuichi Nakai^1,3, Yutaka Matsumura¹, Atsushi Tanemura¹, Kazunori Yokoi¹, Shoichi Matsuda^1,3, Yuumi Nakamura^1,4, Naoya Otani⁵, Mifue Taminato⁵, Koichi Tomita^5,6, Tateki Kubo⁵, Mari Wataya-Kaneda^1,2, Atsushi Kumanogoh⁷, Manabu Fujimoto¹, Rei Watanabe^1,8 rwatanabe@derma.med.osaka-u.ac.jp

Source: eLife. 12/31/2024, p1-24. 24p.

Subject Terms: *BONE marrow, *MTOR inhibitors, *SEMAPHORINS, *KERATINOCYTES, *HOMEOSTASIS, *T cells, KERATINOCYTE differentiation

Three-Year Follow-Up after Intrauterine mTOR Inhibitor Administration for Fetus with TSC-Associated Rhabdomyoma.

Authors: Maász, Anita¹ (AUTHOR), Bodó, Tímea² (AUTHOR), Till, Ágnes¹ (AUTHOR), Molnár, Gábor³ (AUTHOR), Masszi, György⁴ (AUTHOR), Labossa, Gusztáv³ (AUTHOR), Herbert, Zsuzsanna⁵ (AUTHOR), Bene, Judit¹ (AUTHOR), Hadzsiev, Kinga¹ (AUTHOR) hadzsiev.kinga@pte.hu

Source: International Journal of Molecular Sciences. Aug2023, Vol. 24 Issue 16, p12886. 11p.

Subject Terms: *MTOR inhibitors, *TUBEROUS sclerosis, *HEART tumors, *NEUROBEHAVIORAL disorders, *SEIZURES (Medicine), *FETUS, *VAGUS nerve

Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor.

Authors: Artoni, Filippo^1,2 (AUTHOR), Grützmacher, Nina¹ (AUTHOR), Demetriades, Constantinos^1,2,3 (AUTHOR) demetriades@age.mpg.de

Source: Aging Cell. Aug2023, Vol. 22 Issue 8, p1-15. 15p.

Subject Terms: *RAPAMYCIN, *MTOR inhibitors, *MACROLIDE antibiotics, *ANTINEOPLASTIC agents, *IMMUNOSUPPRESSIVE agents

mTOR Inhibitors Modulate the Physical Properties of 3D Spheroids Derived from H9c2 Cells.

Authors: Watanabe, Megumi¹ (AUTHOR) watanabe@sapmed.ac.jp, Yano, Toshiyuki² (AUTHOR) oltomwaits55@gmail.com, Sato, Tatsuya^2,3 (AUTHOR) satatsu.bear@gmail.com, Umetsu, Araya¹ (AUTHOR) araya.umetsu@sapmed.ac.jp, Higashide, Megumi¹ (AUTHOR) megumi.h@sapmed.ac.jp, Furuhashi, Masato² (AUTHOR) furuhasi@sapmed.ac.jp, Ohguro, Hiroshi¹ (AUTHOR) ooguro@sapmed.ac.jp

Source: International Journal of Molecular Sciences. Jul2023, Vol. 24 Issue 14, p11459. 16p.

Subject Terms: *MTOR inhibitors, *CELL culture, *GENE expression, *FIBRONECTINS, *CONNEXIN 43, *RAPAMYCIN, *MOLECULES, *CADHERINS